Key result
Morphine administration significantly improved dyspnoea intensity from baseline to day 1 on both the VAS (67 to 50 mm; p=0.02) and STAS-J (3.3 to 2.6 points; p=0.006) in advanced heart failure.
Why the study?
Morphine relieves dyspnoea in cancer, but its effectiveness and safety for refractory dyspnoea in advanced heart failure required investigation.
Does morphine administration improve refractory dyspnoea in hospitalised patients with advanced heart failure?
Observational (n=28)
Yes
Does morphine administration improve refractory dyspnoea in hospitalised patients with advanced heart failure?
p-value: p=0.02 for VAS, 0.006 for STAS-J
No takes yet. Share an insight, caveat, or question.
Morphine was associated with dyspnoea relief and no acute safety signals in advanced HF; leaves open need for RCTs before practice change.
Hamatani et al. (2023) conducted an observational in Advanced heart failure with refractory dyspnoea (n=28). Morphine administration was evaluated on Dyspnoea intensity changes assessed by Visual Analogue Scale (VAS) and Support Team Assessment Schedule-Japanese (STAS-J) (p=0.02 for VAS, 0.006 for STAS-J). Morphine administration significantly improved dyspnoea intensity from baseline to day 1 on both the VAS (67 to 50 mm; p=0.02) and STAS-J (3.3 to 2.6 points; p=0.006) in advanced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: